Guidelines have done more harm than good

被引:20
作者
Amerling, Richard [1 ,2 ]
Winchester, James F. [1 ,2 ]
Ronco, Claudio
机构
[1] Beth Israel Deaconess Med Ctr, Div Nephrol & Hypertens, New York, NY 10003 USA
[2] St Bortolo Hosp, Dept Nephrol & Intens Care, Vicenza, Italy
关键词
practice guidelines; compliance; renal bone disease; treatment; anemia; arteriovenous fistula;
D O I
10.1159/000110569
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Practice guidelines have proliferated in medicine but their impact on actual practice and outcomes is difficult, if not impossible, to quantify. Though guidelines are based largely on observational data and expert opinion, it is widely believed that adherence to them leads to improved outcomes. Data to support this belief simply does not exist. If guidelines are universally ignored, their impact on treatment and outcomes is minimal. The incorporation of guidelines into treatment protocols and performance measures, as is now common practice in nephrology, increases greatly the likelihood that guidelines will influence practice and hence, outcomes. Practice patterns set up this way may be resistant to change, should new evidence emerge that contradicts certain recommendations. Even if guidelines are entirely appropriate, a 'one-size-fits-all' approach is likely to benefit some, but not all. Certain patients may be harmed by adherence to specific guidelines. Guidelines certainly do not encourage clinicians to consider and treat each patient as an individual. They are unlikely to stimulate original research. They are created by a process that is artificial, laborious and cumbersome. This all but guarantees many guidelines are obsolete by the time they are published. Guidelines are produced with industry support and recommendations often have a major impact on sales of industry products. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:73 / 76
页数:4
相关论文
共 20 条
[1]   Guidelines for guidelines [J].
Amerling, Richard ;
Winchester, James F. ;
Ronco, Claudio .
BLOOD PURIFICATION, 2007, 25 (01) :36-38
[2]  
ARMSTRONG D, 2006, MED J SPIKES ARTICLE
[3]   Changes in the practice of angioaccess surgery: Impact of dialysis outcome and quality initiative recommendations [J].
Ascher, E ;
Gade, P ;
Hingorani, A ;
Mazzariol, F ;
Gunduz, Y ;
Fodera, M ;
Yarkovich, W .
JOURNAL OF VASCULAR SURGERY, 2000, 31 (01) :84-90
[4]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[5]   Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients [J].
Block, G. A. ;
Raggi, P. ;
Bellasi, A. ;
Kooienga, L. ;
Spiegel, D. M. .
KIDNEY INTERNATIONAL, 2007, 71 (05) :438-441
[6]   Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J].
Chertow, GM ;
Burke, SK ;
Raggi, P .
KIDNEY INTERNATIONAL, 2002, 62 (01) :245-252
[7]   Influence of industry on renal guideline development [J].
Coyne, Daniel W. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (01) :3-7
[8]   Normalization of hemoglobin level in patients with chronic kidney disease and anemia [J].
Drueke, Tilman B. ;
Locatelli, Francesco ;
Clyne, Naomi ;
Eckardt, Kai-Uwe ;
Macdougall, Iain C. ;
Tsakiris, Dimitrios ;
Burger, Hans-Ulrich ;
Scherhag, Armin .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20) :2071-2084
[9]   The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Murray, DC ;
Barre, PE .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (01) :53-61
[10]   Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis [J].
Jones, M ;
Ibels, L ;
Schenkel, B ;
Zagari, M .
KIDNEY INTERNATIONAL, 2004, 65 (03) :757-767